On September 18, 2019 Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, reported that its Chief Executive Officer, Panna Sharma, will present at the 8th Annual Drug Repositioning, Repurposing and Rescue Conference in Arlington, VA (Press release, Lantern Pharma, SEP 18, 2019, View Source;utm_medium=rss&utm_campaign=lantern-pharma-ceo-panna-sharma-to-showcase-ai-platform-at-drug-repositioning-repurposing-and-rescue-conference [SID1234539612]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Sharma will present a talk entitled "How Machine Learning, Genomics and AI are Revolutionizing Cancer Drug Development" on Tuesday, September 24, 2019 at 2:45pm ET. Specifically, Sharma will elaborate on why now is an opportune moment for the pharmaceutical industry to leverage these technologies, and how Lantern Pharma is revolutionizing the drug development process by implementing its AI-enabled platform, RADR, to increase clinical trial success rates and reduce timelines and costs. He will also share specifics from how Lantern has leveraged RADR, Lantern’s AI platform, to rescue and accelerate efforts on Lantern’s clinical and preclinical stage programs.
Lantern currently has three drugs in its portfolio (LP100, LP184, LP300) and is using RADR to identify specific patient populations and potential combination mechanisms that are most likely to indicate the highest likelihood of response to that drug, as well as accelerate and de-risk the drug development and rescue process. This targeted approach, according to the company, will help drive down the cost of drug development and improve patient outcomes in cancer drug development and clinical trials. RADR is also used to aid in the rapid development of companion diagnostics (CDx), reducing the time and cost of bringing these cancer drugs to market, which would also positively impact the pharmaceutical, payer and patient community.
"The Drug Repositioning, Repurposing and Rescue Conference provides an excellent setting for the exchange of ideas and progress between pioneers in drug repurposing," said Panna Sharma, CEO of Lantern Pharma. "Lantern is working diligently to repurpose cancer drugs, and we’ve made significant progress in the last year with respect to early-stage clinical results and the constant evolution of our platform. We look forward to presenting this progress at this year’s conference."
The annual Drug Repositioning, Repurposing and Rescue Conference gathers some of the foremost experts in the fields of repositioning and repurposing to discuss patient advocacy efforts, partnerships, systematic repositioning and data analytics, new technologies, regulation and key areas for repurposing.
For more information, visit View Source